Marker Therapeutics, Inc.MRKRNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank57
3Y CAGR-15.1%
5Y CAGR-17.3%
Studio
Year-over-Year Change

Direct costs attributable to producing goods sold

3Y CAGR
-15.1%/yr
vs -44.3%/yr prior
5Y CAGR
-17.3%/yr
Consistent
Acceleration
+29.1pp
Accelerating
Percentile
P57
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$7.31M-45.7%
2024$13.47M+29.3%
2023$10.42M-13.0%
2022$11.97M+278.4%
2021$3.16M-83.2%
2020$18.88M+47.9%
2019$12.76M-89.7%
2018$124.00M+2261.4%
2017$5.25M-
2016$0.00-